NCT00834210

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 171 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	Dapsone	Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
DRUG	Tazarotene	Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2009-02-03
• Last updated: 2011-10-31
• Results posted: 2011-10-31

Locations

1 site across 1 country: United States